Article Text

PDF
PS-015 Toxicity assessment of first-line treatment in metastatic colorectal cancer
  1. A Escolano,
  2. C Pérez,
  3. O Pascual,
  4. I Larrodé,
  5. V Gimeno,
  6. MJ Agustin
  1. Universitary Hospital Miguel Servet, Pharmacy Service, Zaragoza, Spain

Abstract

Background Cancer patients receiving chemotherapy experience a wide range of adverse effects (AE) that may lead to delays in treatment and reductions in dose intensity, which carry the risk of suboptimal outcome.

Purpose To assess the different toxicity profiles of chemotherapy regimens used in first-line treatment of metastatic colorectal cancer (mCRC).

Materials and methods We conducted a retrospective and observational study including patients who started mCRC treatment from October 2011 to June 2012. National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.02, was used to grade toxicity.

Results We identified 79 patients (54% male) with a median age of 66 years old. The rates of grade 1 to grade 4 toxicity are presented in Table 1. Percentages of patients requiring a treatment delay or a dose reduction and those whose treatment was cancelled due to toxicity are shown in Table 2 in the poster.

Abstract PS-015 Table 1
Abstract PS-015 Table 2

Conclusions AE occurred in a high percentage of patients and, despite of their low grade toxicity, reduction, cancellation or delay were required in a significant percentage of patients.

No conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.